



Selecta Biosciences Announces Date of Second Quarter 2019 Financial Results Conference Call

Watertown, Mass., Aug. 01, 2019 – [Selecta Biosciences, Inc.](#) (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced that it plans to issue its second quarter 2019 financial results before the open of the U.S. financial markets on Thursday, August 08, 2019.

At 8:30 a.m. ET that day, Selecta will host a conference call and live audio webcast to discuss second quarter 2019 financial results and provide a corporate update. Investors and the public can access a live and archived webcast of this call via the Investors & Media section of the company's website, <http://selectabio.com>. Individuals may also participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10127459.

About Selecta Biosciences, Inc.

Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform. Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity. The company's current proprietary pipeline includes ImmTOR-powered therapeutic enzyme and gene therapy product candidates. SEL-212, the company's lead product candidate, is being developed to treat chronic refractory gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta's proprietary gene therapy product candidates are in preclinical development for certain rare inborn errors of metabolism and incorporate ImmTOR with the goal of addressing barriers to repeat administration. Selecta is based in Watertown, Massachusetts. For more information, please visit <http://selectabio.com>.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing of future events. All such forward-looking statements are based on



management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to those set forth in the "Risk Factors" section of Selecta's Annual Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, for the quarter ended March 31, 2019, and in other filings that Selecta makes with the SEC. In addition, any forward-looking statements included in this press release represent Selecta's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Selecta specifically disclaims any obligation to update any forward-looking statements included in this press release.

#

For media:

Leticia Diaz
Spectrum Science Communications, Inc.
202-587-2517
ldiaz@spectrumscience.com

For investors:

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com